Foteini V Karakontaki, Efstratios S Panselinas, Vlasios S Polychronopoulos, Athanasios G Tzioufas
Autoimmunity reviews 2021 FebAutoimmune rheumatic diseases (ARD) are characterized by systemic manifestations and multiple organ involvement, including the lung. Interstitial Lung Disease (ILD) is a cardinal manifestation of lung involvement in patients with ARD and is associated with significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are used as first -line treatment. Targeted therapies, such as biological disease modifying antirheumatic drugs (DMARDS) and anti- fibrotic agents are new treatment options. In this review we discuss the role of targeted therapies in patients with ILD secondary to ARD. Copyright © 2020 Elsevier B.V. All rights reserved.
Foteini V Karakontaki, Efstratios S Panselinas, Vlasios S Polychronopoulos, Athanasios G Tzioufas. Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. Autoimmunity reviews. 2021 Feb;20(2):102742
PMID: 33333235
View Full Text